ZTS
$78.23-3.38%
as of close, Oct 27, 2026
☾ AH $78.23 -3.38%
ZTS — Zoetis Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeEEEEEEEEEEEEEEEEEEEEE
60.080.0100.0120.0140.0160.0180.0200.0220.0240.0050.0M$78.23—20162019202120242026
2026-10-27
Price$78.23
MA20$76.04
MA50$106.85
Vol13.4M
Key stats#
Price data
- Price
- $78.23
- YTD price return
- -37.82%
- YTD total return
- -36.85%
- Next earnings
- Nov 5, 2026 · Before open
- Market cap
- 32.3B
- Enterprise value
- 40B
- Shares outstanding
- 413.2M
- 52W low
- $68.77
- 52W high
- $147.93
- From 52W high
- -47.12%
- From 52W low
- +13.76%
- 52W range
- 12%
- Beta
- 0.74
Volume
- Rel volume
- 0.66×
- 30D volume
- 4.2M
- 30D $ vol
- 310.5M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- none
- Insider net 1Y
- −$1.7M
Form 4 transactions by trade date, as filed; latest on file 2026-05-13.
Fundamentals
- Sales (ttm)
- 9.5B
- Sales/share
- $23.03
- EPS (ttm)
- $6.08
- FCF (ttm)
- 2.3B
- FCF/share
- $5.60
- Book value/share
- $7.62
- Net margin
- 27.49%
- ROE
- 83.10%
- ROA
- 17.35%
- Debt / equity
- 2.87×
- Current ratio
- 3.08
Growth (CAGR, ttm) · 10Y
- Sales
- +1.49%+5.00%+5.13%+6.96%
- Net income
- +0.97%+5.73%+6.51%+15.15%
- FCF
- +2.07%+21.69%+6.36%+18.14%
- Shares
- -6.76%-3.53%-2.71%-1.79%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +5.44%+8.55%+8.76%+16.87%
- Sales/share
- +8.86%+8.84%+8.05%+8.91%
- FCF/share
- +9.48%+26.15%+9.31%+20.30%
- Book value/share
- -32.18%-8.81%-3.66%+10.77%
- Dividend/share
- +13.79%+15.01%+18.96%+19.68%
- Price
- -47.00%-20.55%-17.89%+4.84%
- Total return
- -45.98%-19.46%-16.96%+5.76%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 12.9×
- Fwd P/E
- 12.6×
- P/S (ttm)
- 3.4×
- P/B (mrq)
- 10.3×
- P/FCF (ttm)
- 14.0×
- EV/EBITDA (fy)
- 10.0×
- EV/Sales (ttm)
- 4.2×
- FCF yield (ttm)
- 7.16%
- Dividend yield (fwd)
- 2.71%
- Dividend yield (ttm)
- 2.67%
- Dividend/share (fwd)
- $2.12
- Buyback yield (realized, 1y)
- 6.76%
- Shareholder yield (realized, 1y)
- 8.05%
- Buyback yield (cash, ttm)
- 11.27%
- Shareholder yield (cash, ttm)
- 14.02%
Vs own 10Y history
- P/E
- 4th
- P/S
- 3rd
- P/B
- 5th
- P/FCF
- 3rd
Bar = where today’s multiple sits in ZTS’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
-3.38%
5D
-2.26%
1M
+10.11%
3M
+1.70%
YTD
-37.82%
1Y
-46.97%
5Y
-62.67%
Recent filings#
- Oct 138-K · Zoetis Appoints Iris Knobloch to its Board of Directors
- Oct 88-K · Zoetis Declares Fourth Quarter 2026 Dividend
- Aug 6Earnings · Earnings release — EPS $1.87 vs $1.84 est. (+1.6%); revenue $2.47B (−0% y/y) 3.9%
- Aug 68-K · Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer
Financial statements
Open full ZTS financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +8.32% | +0.22% |
| JNJ | Johnson & Johnson | -0.92% | +0.91% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| MRK | Merck & Co. Inc. | -4.68% | +0.86% |
| NVS | Novartis AG | +7.84% | +1.98% |
| TMO | Thermo Fisher Scientific Inc. | +2.67% | +1.19% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
